Atezolizumab monotherapy recommended in NICE draft guidance for untreated advanced lung cancer in adults

Results from an indirect comparison suggest that atezolizumab is as effective as pembrolizumab in delaying disease progression and in extending life.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in